Dana J. Lukin

3.8k total citations
72 papers, 1.4k citations indexed

About

Dana J. Lukin is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Dana J. Lukin has authored 72 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 35 papers in Epidemiology and 22 papers in Surgery. Recurrent topics in Dana J. Lukin's work include Inflammatory Bowel Disease (44 papers), Microscopic Colitis (26 papers) and Eosinophilic Esophagitis (9 papers). Dana J. Lukin is often cited by papers focused on Inflammatory Bowel Disease (44 papers), Microscopic Colitis (26 papers) and Eosinophilic Esophagitis (9 papers). Dana J. Lukin collaborates with scholars based in United States, Canada and Germany. Dana J. Lukin's co-authors include Ellen Scherl, Robert Battat, Randy Longman, James J. Manfredi, Geetha M. Habib, Martin M. Matzuk, Subbarao V. Kala, Michael W. Lieberman, Roberto Barrios and Zheng-Zheng Shi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Dana J. Lukin

62 papers receiving 1.3k citations

Peers

Countries citing papers authored by Dana J. Lukin

Since Specialization

Citations

This map shows the geographic impact of Dana J. Lukin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana J. Lukin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana J. Lukin more than expected).

Fields of papers citing papers by Dana J. Lukin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana J. Lukin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana J. Lukin. The network helps show where Dana J. Lukin may publish in the future.

Co-authorship network of co-authors of Dana J. Lukin

This figure shows the co-authorship network connecting the top 25 collaborators of Dana J. Lukin. A scholar is included among the top collaborators of Dana J. Lukin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana J. Lukin. Dana J. Lukin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IgG-seq identifies immune-reactive enteric bacteria in Crohn’s disease with spondyloarthritis 2025 ·Gut Microbes ·(unknown), (unknown), (unknown), (unknown), (unknown), Dana J. Lukin, Ellen Scherl, Randy Longman	3
2	Donor composition and fiber promote strain engraftment in a randomized controlled trial of fecal microbiota transplant for ulcerative colitis 2025 ·Med ·Lasha Gogokhia, (unknown), Alex Grier, Manabu Nagayama, (unknown), (unknown), (unknown), Charles D. Ericsson, Sarah Ben Maamar, (unknown), Robert Battat, Ellen Scherl, Dana J. Lukin, Randy Longman	1
3	The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis 2025 ·Inflammatory Bowel Diseases ·Esther Liu, Anjile An, (unknown), Robert Battat, Randy Longman, Ellen Scherl, (unknown), Dana J. Lukin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
4	Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry 2024 ·Clinical Gastroenterology and Hepatology ·Steven H. Itzkowitz, Yue Jiang, Cristina Villagra, Jean‐Frédéric Colombel, (unknown), Dana J. Lukin, David M. Faleck, Ellen Scherl, Shannon Chang, Lea Ann Chen, Seymour Katz, (unknown), Arun Swaminath, Francesca Petralia, (unknown), David B. Sachar, Lina Jandorf, Jordan E. Axelrad	5
5	The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis 2024 ·Cell Reports Medicine ·Svetlana Lima, Sílvia Pires, (unknown), (unknown), Wen‐Bing Jin, Andrew R. Marderstein, (unknown), (unknown), Monica Viladomiu, Gregory Putzel, (unknown), (unknown), (unknown), Alex Grier, Chun‐Jun Guo, Dana J. Lukin, Lisa A. Mandl, Ellen Scherl, Randy Longman	19
6	The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease 2023 ·Crohn s & Colitis 360 ·(unknown), (unknown), (unknown), Rachel Niec, Randy Longman, (unknown), Dana J. Lukin, Ellen Scherl, Robert Battat	3
7	P630 Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies 2023 ·Journal of Crohn s and Colitis ·S Schreiber, A. J. Lim, Ana P. Lacerda, Jessica R. Allegretti, Kenji Watanabe, Dana J. Lukin, (unknown), (unknown), (unknown), Qian Zhou, (unknown), Édouard Louis	2
8	Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel 2022 ·The American Journal of Gastroenterology ·Parambir S. Dulai, Victoria Rai, Laura E. Raffals, Dana J. Lukin, David Hudesman, Gursimran Kochhar, Oriana M. Damas, Jenny Sauk, Alexander N. Levy, M. Anthony Sofia, Anne Tuskey, Parakkal Deepak, Andrés Yarur, Anita Afzali, Ashwin N. Ananthakrishnan, Raymond K. Cross, Stephen B. Hanauer, Corey A. Siegel	5
9	Joint Disease Activity in Inflammatory Bowel Disease–associated Peripheral Spondyloarthritis Stratifies Therapeutic Response 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), A Lavergne, Robert Battat, Waseem Ahmed, Monica Schwartzman, (unknown), (unknown), Peter Siao Tick Chong, Gabriele E. Sonnenberg, (unknown), Dana J. Lukin, Ellen Scherl, Randy Longman	4
10	Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability 2021 ·Clinical Gastroenterology and Hepatology ·Maia Kayal, Ryan C. Ungaro, (unknown), Kanika Kamal, Manasi Agrawal, Shirley Cohen‐Mekelburg, Jordan E. Axelrad, Adam S. Faye, Ellen Scherl, Garrett Lawlor, Keith Sultan, Dana J. Lukin, Marla C. Dubinsky, Jean‐Frédéric Colombel	11
11	S874 Comparative Efficacy of TNF Antagonists and Ustekinumab in Post-Operative Crohn’s Disease 2021 ·The American Journal of Gastroenterology ·Waseem Ahmed, (unknown), (unknown), (unknown), Daniel W. L. Lai, (unknown), (unknown), Randy Longman, Dana J. Lukin, Ellen Scherl, Robert Battat	2
12	Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 2021 ·Clinical Gastroenterology and Hepatology ·Waseem Ahmed, (unknown), Anand Kumar, Paul J. Christos, Randy Longman, Dana J. Lukin, Ellen Scherl, Robert Battat	109
13	Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis 2020 ·Journal of Gastroenterology ·Anand Kumar, Dana J. Lukin, Robert Battat, Monica Schwartzman, Lisa A. Mandl, Ellen Scherl, Randy Longman	11
14	Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications 2020 ·Digestive Diseases and Sciences ·Anand Kumar, (unknown), (unknown), Joshua D. Miller, Dana J. Lukin	17
15	Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio‐economic factors 2019 ·Alimentary Pharmacology & Therapeutics ·Manasi Agrawal, Shirley Cohen‐Mekelburg, Maia Kayal, Jordan E. Axelrad, (unknown), (unknown), Kanika Kamal, Adam S. Faye, (unknown), Ellen Scherl, Garrett Lawlor, Keith Sultan, Dana J. Lukin, Jean‐Frédéric Colombel, Ryan C. Ungaro	22
16	Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors 2018 ·Indian Journal of Gastroenterology ·Anand Kumar, Mimi Kim, Dana J. Lukin	12
17	P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium 2017 ·Inflammatory Bowel Diseases ·Eugenia Shmidt, Adam C. Winters, (unknown), Khadija Chaudrey, Gursimran Kochhar, Malav P. Parikh, Michelle Luo, (unknown), Brigid S. Boland, Siddharth Singh, David Hudesman, Dana J. Lukin, William J. Sandborn, Bo Shen, Corey A. Siegel, Edward V. Loftus, Sunanda V. Kane, Bruce E. Sands, Jean–Frédéric Colombel, Parambir S. Dulai	2
18	The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium 2016 ·The American Journal of Gastroenterology ·Parambir S. Dulai, Siddharth Singh, Xiaoqian Jiang, Farhad Peerani, Neeraj Narula, Khadija Chaudrey, Diana Whitehead, David Hudesman, Dana J. Lukin, Arun Swaminath, Eugenia Shmidt, Shuang Wang, Brigid S. Boland, John T. Chang, Sunanda V. Kane, Corey A. Siegel, Edward V. Loftus, William J. Sandborn, Bruce E. Sands, Jean‐Frédéric Colombel	216
19	p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints 2014 ·Molecular Cancer Research ·Dana J. Lukin, Luis A. Carvajal, (unknown), Lois Resnick‐Silverman, James J. Manfredi	69
20	Effect of Comorbid Conditions on Adherence to Colorectal Cancer Screening 2012 ·Journal of Cancer Education ·Dana J. Lukin, Lina Jandorf, (unknown), Linda Thélèmaque, Jennifer Christie, Steven H. Itzkowitz, Katherine N. DuHamel	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact